EcoDrugPlus

Phosphodiesterase 5a

Ensembl ID : ENSRFEG00010007136
Gene Symbol: PDE5A
1 Cross references
220 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSRFEG00010005521
Gene Symbol: PDE7A
1 Cross references
253 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSRFEG00010004294
Gene Symbol: PDE7B
1 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSRFEG00010004823
Gene Symbol: PDE9A
1 Cross references
280 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSRFEG00010019671
Gene Symbol: PIK3R1
1 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSRFEG00010019200
Gene Symbol: PIK3R2
1 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSRFEG00010000731
Gene Symbol: PIK3R3
1 Cross references
274 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSRFEG00010006427
Gene Symbol: PIK3R5
1 Cross references
255 Possible Orthologues:

Phospholipase A2 Group Iia

Ensembl ID : ENSRFEG00010018203
Gene Symbol: PLA2G2A
1 Cross references
172 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSRFEG00010018257
Gene Symbol: PLA2G5
1 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSRFEG00010007125
Gene Symbol: PLA2G7
1 Cross references
203 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSRFEG00010016268
Gene Symbol: PLA2G10
1 Cross references
249 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).